COVER STORY

FROM P I T T C O N

ANALYZING VACCINES Complicated mixtures that make up therapeutics vaccines provide diverse analytical challenges CELIA HENRY ARNAUD, C&EN WASHINGTON

TODAY, PEOPLE AROUND THE WORLD

face the threat of infectious diseases such as ADDS and avian flu. Because preventing these diseases is far preferable to treating an epidemic,

the development of vaccines is desirable. Historically, vaccines have been complex mixtures that were difficult to characterize and often not well-defined. Now, scientists have tools to better define such complicated mixtures. Moreover, subunit vaccines consist­ing of only a few components that are easier to characterize are becoming more popular. In a symposium at Pittcon, researchers discussed efforts to develop vaccines for a number of diseases, including, in many cases, the associated analytical challenges.

One of the most recent threats is the H5N1 strain of avian influ­enza virus that has emerged in Asia and made its way to Europe and Africa. Richard Webby, a virologist at St. Jude Children's Research Hospital in Memphis, described the search for new vac­cines against H5N1.

Vaccines against flu viruses generally exploit the fact that the virus's genome is organized into eight separate pieces of RNA. Traditionally, newvaccine strains are generated by randomly re­shuffling the pieces of RNA from a laboratory strain and the tar­get strain until a hybrid vaccine strain is achieved that contains six pieces of RNA from the lab strain and two pieces from the target strain.

Vaccine researchers no longer need to rely on random reshuf­fling, Webby said. Using reverse genetics and a plasmid replication system, they can dictate the pieces of RNA in the vaccine strain. (Plasmids are circular pieces of DNA usu­ally found in bacteria.) Reverse genetics is much faster than relying on random reshuf­fling, Webby said, but the process still takes months to find a virus strain that is a good vaccine candidate.

Vaccines are typically grown in chick­en eggs. But the highly pathogenic virus H5N1 is difficult to produce this way be­cause it kills the embryos in the chicken eggs, Webby pointed out. He added that there's still plenty to learn about the pathogenicity of flu viruses such as H5N1, but a major cause appears to be a stretch of basic amino acids in hemagglutinin, one of two surface proteins that charac­terize flu viruses. For a flu virus to be infective, hemagglutinin must be cleaved

TROUBLE SPOTS Researchers using mass spectrometry were able to identify seven sites of deamidation (arrows) in the anthrax rPA antigen. The pink dots represent the side chains of the seven asparagines that undergo deamidation. The pink arrows indicate sites that had been previously predicted. The other four sites (blue arrows) had not been predicted by models.

by a protease at that particular site. Usu­ally, the proteases needed for such cleav­age are found only in the respiratory tract. When additional basic amino acids are inserted at the site, the hemagglutinin becomes susceptible to other proteases,

thereby increasing the virus's pathogenicity. By removing a string of these basic amino

acids from the virus, Webby and his cowork­ers generated an "attenuated" virus that is less pathogenic. In a ferret model of flu, the immune response generated by a vaccine derived from the attenuated virus was such that none of the animals even demonstrated clinical signs of infection. This vaccine is now in clinical trials.

A more widespread virus is the human papillomavirus (HPV), which can cause cer­vical cancer. More than 24 million women in the U.S. and 600 million women worldwide are infected with the virus. Robert D. Sitrin, the executive director of bioprocess and bio-analytical research at Merck Research Labo­ratories in West Point, Pa, described some of the analytical development that has gone into Gardasil, Merck's candidate vaccine for HPV. A New Drug Application has been filed with the Food & Drug Adrninistration and is be­

ing fast-tracked, Sitrin said. The vaccine consists of re­

combinant "viruslike particles" (VLPs) made with a surface protein from the virus. This so-called LI protein forms a pen-tamer called a capsomere that self-assembles into the VLP. The entire structure has a mo­lecular weight of about 20 mil­lion daltons.

The analytical challenge was in ensuring that each lot of vac­cine is comparable with the lot used in clinical trials, and the analytical tests fall into the broad categories of characteriza­tion and comparability assays. The characterization tests are used to initially define the prod­uct. Once those tests are done, they don't need to be repeated. Comparability tests are simpler assays used to check each lot. For example, once a vaccine's sequence has been determined by mass spectrometry, its rough molecular weight in subsequent lots is checked by poryacrylamide gel electrophoresis.

The key comparability test, Sitrin said, is for potency. The challenge is demonstrating that an analytical method gives the same result as animal studies.

Sitrin described a method that Merck uses called in vitro relative potency, or IVRP. In this method, an antibody is used to map the binding sites on the VLP. Once the bind­ing sites have been identified, they can be tested by using a simple immunoassay. The

5 2 C&EN / APRIL 3, 2006 W W W . C E N - 0 N L I N E . O R G

CANCER VACCINE Viruslike particles from four types of human papilloma virus are used in Merck's HPV vaccine to prevent cervical cancer and genital warts. A surface rendering of a VLP derived from HPV-18 is shown here.

IVRP test indicates whether the VLP is properly assembled. Improperly assembled VLPs evoke a lower immune response. This method is more precise than other tests for potency and does not require killing ani­mals, Sirtin said.

On another front, Vincent Turula, asso­ciate director of analytical development at Wyeth Research in Durham, N.C., spoke about the process that Wyeth goes through to update its analytical methods for conju­gate vaccines.

Some vaccines contain more than just pro­teins. Conjugate vaccines are combinations of molecules, typically proteins bound to poly­saccharides. Vaccine assembly starts with na­tive viral polysaccharides, which vary in size and chemical composition. The polysaccha­rides are then activated to generate locations for attachment of "cross-reactive material," which is the part of the conjugate vaccine that generates the immune response.

Wyeth regularly evaluates its analytical

COURTESY OF MERCK AND THE NATIONAL RESOURCE FOR AUTOMATED MOLECULAR

MICROSCOPY/SCRIPPS

tests to see which ones should be im­proved or replaced, Turula said. The more variable an as say, the higher the pri­ority to improve it. One such test is the spectropho-tometric anthrone assay used to quantitate polysaccharides. In this assay, an anthrone reagent reacts with the component monosaccharides in the open form. The assay involves multiple steps, but Wyeth has shortened the assay time and reduced analyst bias with an automated liquid-han­dling system.

Sometimes completely new methods are needed, Turula said. For example, Wyeth has evaluated the use of capillary electro­phoresis with laser-induced fluorescence detection for polysaccharide quantitation, he explained. Other newer techniques in­clude multiple-angle laser light scattering

(MALLS) to de­termine the vac­cine's molecular weight and micel-lar electrokinetic

chromatography to quantitate residual free

protein. "Classical tests are important and useful,"

Turula said, "but they should be updated and improved."

Another user of MALLS is Diana Tier-ra, a chemist in analytical development at Chiron in Emeryville, Calif. She described her group's work to develop techniques for analyzing the HIV envelope protein gpl40. This trimer on the surface of the virus par­ticle is being used as an antigen in HIV vac­cines. A key required analysis is detennining gpl40's higher order structure. Higher order structure matters because FDA requires companies to completely characterize all structural levels of biological components, including quaternary structure, which in­dicates the degree of association among

D8 SCREENLAB GET THE FULL

PICTURE: RAMAN AND XRD*

IN ONE SCREEN

BRUKER ADVANCED X-RAY SOLUTIONS North America: BRUKER AXS INC ν Tel. (+1) (608) 276-3000 ν Fax (+1) (608) 276-3006 ν www.bruker-axs.com ν info@bruker-axs.com All other countries: BRUKER AXS GMBH ν Tel. (49) (721 ) 595-2888 ν Fax (+49) (721 ) 595-4587 ν www.bruker-axs.de ν info@bruker-axs.de

Request more at AdlnfoNow.org

W W W . C E N - 0 N L I N E . O R G C&EN / APRIL 3, 2006 5 3

COVER STORY

monomer units. By measuring the molecular weight, through size exclusion chromatog­raphy with MALLS as a detector (SEC-MALLS), they can tell whether the protein is forming dimers, trimers, or higher order associations.

Not all vaccines are for viruses. Bradford S. Powell, a researcher at the Army Medical Research Institute of Infectious Diseases in Frederick, Md., is helping to develop vac­cines against plague and anthrax, both of which are caused by bacteria. Current vac­

cines for these "diseases of antiquity" are not particularly advanced from the first vaccines introduced decades ago, Powell said. The current vaccine for anthrax causes physical reactions, and a person requires six doses to acquire immunity. The U.S.-licensed plague vaccine is more problematic and no longer manufactured, Powell said.

The new vaccines for plague and anthrax that Powell is helping to analyze will consist of purified bacterial subunits: the rPA protein for anthrax and the rFl-V fusion protein for

plague. Both of these vaccines present ana­lytical challenges related to quality control because of their structural heterogeneity.

IN THE CASE of the anthrax vaccine, the rPA antigen exists in several isoforms likely caused by deamidation. In this type of spon­taneous chemical degradation, asparagine or ghitamine residues hydrolyticalry lose their amide group, but spécifie demonstration of such changes has been difficult. A common but indirect test for deamidation is a com­mercial assay that measures the presence of one end product, isoaspartate, but this test is not définitive for deamidation and does not indicate the number or locations of the modified amino acids. Liquid chromatog­raphy coupled with electrospray tandem mass spectrometry turned out to be the best method for pinpointing deamidation, Powell said. But even this method requires manual checks of automated assignments for site-specific deamidation, he added.

Powell reported that the usual model for forecasting deamidation is imprecise for rPA. He found seven sites of deamidation, only three of which were predicted by the model and another of which was predicted to have a deamidation half-life of 2 million days. If people rely on the model to guide where they should monitor a protein for deamidation for quality control, they may not choose an actively modified site, Powell said. 'The take-home message is that it's not yet easy to measure deamidation in proteins, and predictive models, though good, are still incomplete,,, he told C&EN.

On the other hand, the challenge for the plague rFl-V antigen, a fusion of two proteins, is that it aggregates, thereby com­plicating complete characterization of the biological product. Powell characterized all levels of structure, from primary to qua­ternary, to identify the culprit and also to establish whether aggregation was a con­sequence of unnatural fusion between the two subcomponent antigens.

After eliminating primary, secondary, and tertiary structure perturbations as possible causes of aggregation, Powell turned to SEC-MALLS to determine quaternary structure. Under physiological conditions, the fusion protein appeared to be a tetramer, whereas the Fl subcomponent appeared to aggregate as a 100-mer. Therefore, aggregation is caused by the Fl subunit of the fusion protein, but the fusion protein architecture reduces this tendency, according to Powell.

Vaccines are important weapons against infectious diseases. The development of new analytical tools to characterize these complex products will help bring new vac­cines to fruition. •

And all this time you thought you were

saving for retirement

Don't let a serious accident or illness force you to dip

into your savings to cover your medical bills. Enhance

your current coverage with ACS-endorsed Excess Major

Medical. The plan strengthens your current coverage,

and includes convalescent home care, home health care,

private duty nursing coverage and more.

For more information*, call

1-800-503-9230 Coverage may vary and may not be available in all states, including features, costs, eligibility, renewability, limitations and exclusions.

MARSH Affinity Group Services a service of Seabury & Smith

www.personal-plans.com/acs Underwritten by:

The United States Life Insurance Company in the City of New York, A member company of American International Group, Inc. 3141002 27500 (4/06) ©Seabury & Smith, Inc. 2006

AG3619

5 4 C&EN / APRIL 3. 2006 W W W . C E N - 0 N L I N E . O R G